Murthy SB, Biffi A, Falcone GJ, et al. - In a multicenter cohort, researchers explored the connection between antiplatelet therapy after intracerebral hemorrhage (ICH) and functional outcomes. Data were meta-analyzed from the Massachusetts General Hospital ICH registry (n = 1,854), the Virtual International Stroke Trials Archive database (n = 762), and the Yale stroke registry (n = 185). The sample consisted of 2,801 ICH patients. Two hundred eighty-eight ICH patients were started on antiplatelet medications after ICH. After ICH, antiplatelet therapy appeared safe and was not linked to all-cause mortality or functional outcome, regardless of the location of the hematoma. To determine the effects and harms of antiplatelet therapy after ICH, randomized clinical trials are required.